SecBot SecBot
8-K ·Filed Jun 2, 2026

MNKD

MANNKIND CORP
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001193125-26-252544
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This is a transformative regulatory catalyst that removes the last postmarketing requirement and expands the addressable market. Monitor upcoming quarterly results for initial pediatric prescription trends and any guidance update on revenue contribution.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.43
T+0 close · Jun 2, 2026 · via day close
Latest settled
+19.24%
T+60 · $4.09
Vs SPY
+18.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $3.43entry
  2. T+1 · 6mo ago −2.04%α −1.35% · $3.36
  3. T+5 · 5mo ago +4.08%α +7.05% · $3.57
  4. T+20 · 5mo ago +18.08%α +19.64% · $4.05
  5. T+60 · 3mo ago +19.24%α +18.13% · $4.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in children and adolescents aged 6+ with type 1 and type 2 diabetes. This also fulfills the last remaining postmarketing requirement from the original 2014 approval, removing a key regulatory overhang and opening a new patient population of over 350,000 U.S. children with diabetes.

Key Facts

  • FDA approved Afrezza for pediatric use in patients aged 6 and older with type 1 and type 2 diabetes.
  • Over 350,000 U.S. children and adolescents live with diabetes, majority type 1 requiring lifelong insulin.
  • Pediatric sBLA fulfills the last remaining postmarketing requirement from the original June 27, 2014 approval letter.
  • Approval date: May 29, 2026; 8-K filed June 2, 2026.

Financial Impact

Opens a new pediatric market of >350,000 patients; no specific revenue guidance provided in filing.

revenue

Risk Factors

  • Pediatric adoption may be slower than expected due to competition from established insulin delivery methods.
  • No financial terms or revenue projections disclosed in the filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-252544
Document: 0001193125-26-252544-index-headers.html0001193125-26-252544
Document: 0001193125-26-252544-index.html0001193125-26-252544
Document: 0001193125-26-252544.txt0001193125-26-252544

Track record

17 reports on MNKD

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Viewing Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026